Jacobus Lubsen

Summary

Publications

  1. pmc Subgroup effects despite homogeneous heterogeneity test results
    Rolf H H Groenwold
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    BMC Med Res Methodol 10:43. 2010
  2. ncbi Combined endpoints: can we use them?
    Jacobus Lubsen
    SOCAR Research SA, Nyon, Switzerland
    Stat Med 21:2959-70. 2002
  3. ncbi Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions
    Jacobus Lubsen
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    J Clin Epidemiol 60:720-6. 2007
  4. ncbi Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
    Jacobus Lubsen
    SOCAR Research SA, Nyon, Switzerland
    J Hypertens 23:641-8. 2005
  5. ncbi Epidemiology: indeed "quo vadis"?
    Jacobus Lubsen
    Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
    Eur J Epidemiol 19:749-50. 2004
  6. ncbi Quality management of a large randomized double-blind multi-centre trial: the ACTION experience
    Bridget Anne Kirwan
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    Contemp Clin Trials 29:259-69. 2008
  7. ncbi Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience
    Bridget Anne Kirwan
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    Contemp Clin Trials 28:720-9. 2007
  8. ncbi Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College, Dovehouse Street, London SW3 6LY, UK
    J Clin Epidemiol 60:727-33. 2007
  9. pmc A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure
    Gerasimos S Filippatos
    University of Athens, Athens, Greece
    Am J Cardiol 101:1772-6. 2008
  10. ncbi Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study
    Anthony M Dart
    Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia
    Eur J Echocardiogr 8:275-83. 2007

Collaborators

Detail Information

Publications23

  1. pmc Subgroup effects despite homogeneous heterogeneity test results
    Rolf H H Groenwold
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    BMC Med Res Methodol 10:43. 2010
    ..Lack of demonstrable statistical heterogeneity, however, might obscure clinical heterogeneity, meaning clinically relevant subgroup effects...
  2. ncbi Combined endpoints: can we use them?
    Jacobus Lubsen
    SOCAR Research SA, Nyon, Switzerland
    Stat Med 21:2959-70. 2002
    ....
  3. ncbi Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions
    Jacobus Lubsen
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    J Clin Epidemiol 60:720-6. 2007
    ..Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question...
  4. ncbi Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
    Jacobus Lubsen
    SOCAR Research SA, Nyon, Switzerland
    J Hypertens 23:641-8. 2005
    ..To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension...
  5. ncbi Epidemiology: indeed "quo vadis"?
    Jacobus Lubsen
    Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
    Eur J Epidemiol 19:749-50. 2004
  6. ncbi Quality management of a large randomized double-blind multi-centre trial: the ACTION experience
    Bridget Anne Kirwan
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    Contemp Clin Trials 29:259-69. 2008
    ..Unequivocal operational definitions of the procedural concepts that characterize randomized clinical trials should not only be the basis of QM, but also of reporting results...
  7. ncbi Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience
    Bridget Anne Kirwan
    SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
    Contemp Clin Trials 28:720-9. 2007
    ..The final diagnosis was always made by a critical events committee (CEC) using standard criteria...
  8. ncbi Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College, Dovehouse Street, London SW3 6LY, UK
    J Clin Epidemiol 60:727-33. 2007
    ..Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data...
  9. pmc A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure
    Gerasimos S Filippatos
    University of Athens, Athens, Greece
    Am J Cardiol 101:1772-6. 2008
    ..81; p=0.044). In conclusion, a history of hypertension was associated with increased risk of hospitalization for stroke among patients with heart failure who were balanced in all measured baseline covariates, including blood pressure...
  10. ncbi Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study
    Anthony M Dart
    Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia
    Eur J Echocardiogr 8:275-83. 2007
    ..To evaluate the relationship between echocardiographic cardiac function and outcome in patients with stable symptomatic angina...
  11. ncbi Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease
    Jan Erik Otterstad
    Hospital of Vestfold, Toensberg, Norway
    Scand Cardiovasc J 40:152-9. 2006
    ..Evaluate the prevalence, incidence and impact on prognosis of existing and new onset atrial fibrillation (AF) in patients with stable, symptomatic coronary artery disease...
  12. pmc Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients
    Tim C Clayton
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 331:869. 2005
    ..To derive a risk score for the combination of death from all causes, myocardial infarction, and disabling stroke in patients with stable symptomatic angina who require treatment for angina and have preserved left ventricular function...
  13. ncbi A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  14. ncbi Safety of nifedipine GITS in stable angina: the ACTION trial
    Philip A Poole-Wilson
    Department of Cardiac Medicine, Imperial College, London, UK
    Cardiovasc Drugs Ther 20:45-54. 2006
    ..9 years...
  15. ncbi Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
    Philip A Poole-Wilson
    Cardiac Medicine, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Lancet 364:849-57. 2004
    ..We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris...
  16. ncbi Outcome following percutaneous transluminal coronary angioplasty performed before 1990
    Samuel F Mpyisi
    Division of Cardiology, Center Hospitalier Universitaire Vaudois CHUV, Rue du Bugnon 17, 1011 Lausanne, Switzerland
    J Interv Cardiol 15:355-61. 2002
    ..The short-term observations are consistent with results reported by the other follow-up studies. In addition, the study found a total survival rate 14 years after a first PTCA of 69% and 47% of the cohort remained event free...
  17. ncbi Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  18. ncbi Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre Madrid, Spain
    J Hypertens 25:1711-8. 2007
    ..Little data is available concerning the prognostic implications of renal function abnormalities, their evolution over time and the effects of nifedipine on such abnormalities in patients with stable angina pectoris...
  19. ncbi Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
    Philip A Poole-Wilson
    Lancet 359:2199; author reply 2203-4. 2002
  20. ncbi Clinical course of isolated stable angina due to coronary heart disease
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur Heart J 28:1928-35. 2007
    ..To describe the clinical course of patients with stable angina due to coronary heart disease without a history of cardiovascular (CV) events or revascularization (isolated angina)...
  21. ncbi Variable impact of combining fatal and nonfatal end points in heart failure trials
    Hicham Skali
    Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 114:2298-303. 2006
    ..Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs...
  22. ncbi The development of heart failure in patients with stable angina pectoris
    George C Sutton
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Heart Fail 9:234-42. 2007
    ..To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset...